Saturday 17 October 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow KALA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 3 | — | — | — | — | — |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
— | — | — | 8.45 | 7.08 | 55.95 | 20.81 | — | — | — |
Altman Z-Score |
— | — | — | (11.18) | (7.31) | (1.37) | (3.29) | — | — | — |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | (23.53) | (14.72) | (3.52) | (6.40) | — | — | — |
P/Operating CF |
— | — | — | (3.54) | (2.85) | (13.73) | (6.94) | — | — | — |
Beneish M-Score |
— | — | — | — | (3.71) | (2.78) | — | — | — | — |
P/B ratio |
— | — | — | 2.56 | 4.73 | 3.56 | 4.26 | — | — | — |
Price to Tangible BV |
— | — | — | 2.56 | 4.73 | 3.56 | 4.26 | — | — | — |
EV/Sales |
— | — | — | 5.21 | 7.19 | 43.41 | 18.68 | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
— | — | — | (0.38) | (0.75) | (3.05) | (1.22) | — | — | — |
EV/FCF |
— | — | — | (0.38) | (0.74) | (2.98) | (1.21) | — | — | — |
Quick Ratio |
3.03 | 3.02 | 6.10 | 2.74 | 2.93 | 7.34 | 3.92 | 10.11 | 7.70 | 8.20 |
Current Ratio |
3.81 | 3.11 | 6.33 | 3.35 | 3.32 | 7.71 | 4.26 | 10.41 | 7.75 | 8.23 |
Net Debt/EBITDA |
0.19 | 0.41 | 0.33 | 0.23 | (0.01) | 0.85 | 0.15 | 1.56 | 2.45 | 1.11 |
Debt/Assets |
0.00% | 63.26% | 68.46% | 59.78% | 68.48% | 33.29% | 46.99% | 31.99% | 16.01% | 20.84% |
Debt/Equity |
0.00 | 2.85 | 5.10 | 2.74 | 5.68 | 0.74 | 2.44 | 0.67 | 0.21 | 0.32 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.03 | 0.06 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.19 | 0.76 | 0.66 | 1.76 | 0.76 | 0.87 | 0.98 | 0.81 | 0.81 | 0.82 |
Capex/Depreciation |
0.04 | (0.14) | (0.36) | (0.10) | (0.32) | (0.99) | (0.74) | (2.52) | (0.64) | (0.38) |
Interest Coverage |
(11.95) | (7.09) | (6.82) | (11.24) | (15.54) | (11.20) | (10.40) | (19.53) | (39.13) | (42.59) |
| (279.19%) | (388.29%) | (318.75%) | (250.56%) | (244.19%) | (160.89%) | (140.12%) | (68.57%) | (4,403.86%) | (3,460.30%) | |
| (83.05%) | (69.12%) | (59.12%) | (39.62%) | (79.00%) | (55.50%) | (50.28%) | (39.55%) | (51.83%) | (143.18%) | |
ROIC |
0.00% | 0.00% | 0.00% | (13,403.22%) | (449.62%) | (297.33%) | (329.12%) | (848.20%) | 0.00% | 0.00% |
Return on Tangible Assets |
(385.65%) | (105.25%) | (93.20%) | (73.89%) | (159.04%) | (68.49%) | (113.12%) | (41.15%) | (41.74%) | (81.54%) |
Average Days of Receivables |
— | — | — | 0.00 | 498.30 | 551.00 | 694.85 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 453.57% | 102.45% | 288.46% | 449.05% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,670.99% | 934.71% | 1,274.25% | 1,070.38% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 180.06% | 143.13% | 209.24% | 164.49% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | 0.37 | 0.02 | 0.14 | (0.15) | — | — | — |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | — | — | (94.15%) | (179.34%) | (29.65%) | (74.80%) | — | — | — |
Free Cash Flow Yield |
— | — | — | (162.89%) | (137.04%) | (26.03%) | (74.42%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 128.03 | 427.38 | 302.95 | 443.36 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(196.26) | (387.11) | (574.63) | (2,595.66) | (4,115.40) | (4,318.76) | (6,767.88) | (5,058.04) | (7,412.61) | (54,696.00) |
Capex per Share |
(0.09) | (2.74) | (11.58) | (6.55) | (30.19) | (92.48) | (97.45) | (147.48) | (104.35) | (306.00) |
Free Cash Flow per Share |
(196.36) | (389.86) | (586.21) | (2,602.20) | (4,145.59) | (4,411.24) | (6,865.33) | (5,205.51) | (7,516.96) | (55,002.00) |
Cash per Share |
46.36 | 674.32 | 1,047.22 | 2,318.91 | 3,580.91 | 7,311.43 | 6,237.15 | 15,971.78 | 24,905.43 | 90,944.00 |
Shareholders Equity per Share |
42.92 | 162.48 | 154.40 | 624.14 | 638.94 | 4,761.67 | 2,167.30 | 9,811.03 | 19,495.43 | 61,258.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.02 |
Book value per Share |
42.92 | 162.48 | 154.40 | 624.14 | 638.94 | 4,761.67 | 2,167.30 | 9,811.03 | 19,495.43 | 61,258.00 |
Free Cash Flow |
(32.01) | (29.59) | (28.49) | (79.11) | (109.03) | (92.64) | (94.05) | (55.70) | (34.58) | (27.50) |
Working Capital |
7.00 | 35.84 | 44.52 | 60.26 | 86.94 | 149.15 | 80.71 | 160.02 | 100.34 | 40.08 |
Capital Expenditures |
(0.01) | (0.21) | (0.56) | (0.20) | (0.79) | (1.94) | (1.33) | (1.58) | (0.48) | (0.15) |
Net Current Asset Value |
7.00 | 9.65 | 4.43 | 18.10 | 1.74 | 49.77 | (19.15) | 61.04 | 88.35 | 29.93 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.05 | 0.07 | 0.31 | 0.22 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 2.01 | 2.07 | 4.91 | 0.92 | 0.62 | 0.67 | 0.29 | 0.96 | 0.68 |
Cash ROIC |
(219.93%) | (30.01%) | (29.46%) | (55.96%) | (52.81%) | (28.30%) | (50.12%) | (16.07%) | (15.51%) | (32.07%) |
Accounts Receivable Turnover |
— | — | — | 0.50 | 0.90 | 0.60 | 0.97 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.66 | 1.24 | 1.50 | 0.50 | 0.29 | 0.58 | 0.27 |
Inventory Turnover |
— | — | — | 0.00 | 0.59 | 0.64 | 0.46 | 0.22 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 403.78 | 436.45 | 198.32 | 457.70 | 2,081.46 | 682.32 | 1,225.27 |
Days of Inventory on Hand |
— | — | — | 0.00 | 769.64 | 601.51 | 844.88 | 1,565.10 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 7.77 | 12.47 | 10.58 | 6.29 | 6.29 | — | — |
Average Payables |
0.81 | 0.77 | 1.88 | 3.87 | 3.31 | 2.12 | 3.98 | 3.32 | 1.10 | 1.10 |
Average Inventory |
— | — | — | — | 6.93 | 4.94 | 4.37 | 4.37 | — | — |
Average Assets |
32.49 | 55.72 | 71.38 | 113.12 | 180.52 | 187.96 | 187.64 | 168.76 | 81.44 | 23.16 |
Average Common Equity |
9.66 | 9.92 | 13.24 | 17.89 | 58.40 | 64.84 | 67.34 | 97.33 | 0.96 | 0.96 |
Columns are period end dates